Epstein–Barr virus peptide–major histocompatibility complex complex (EBV peptide–MHC complex)

The **Epstein–Barr virus peptide–major histocompatibility complex (EBV peptide–MHC) complex** refers to cellular complexes formed when short peptide fragments derived from EBV proteins are bound by major histocompatibility complex (MHC) molecules, predominantly MHC class I or class II, and displayed on the surface of infected cells[2][1][4]. These complexes are recognized by T cell receptors (TCRs) on cytotoxic T lymphocytes or helper T cells, triggering specific immune responses central to the control of EBV infection and the prevention of EBV-associated diseases[6][5]. MHC class I–restricted EBV peptide presentation is essential for activation of CD8+ CTLs, which are the main immune effectors for eliminating EBV-infected cells[6][5][1]. Key epitopes include peptides from latent antigens such as EBNA, LMP1, and lytic cycle proteins, presented by diverse HLA alleles including HLA-A*02:01, HLA-A*11:01, and HLA-B*44 subtypes, with differential peptide binding and immune activation efficiency depending on the allele[1][5][6]. The immune recognition of these complexes is crucial for both the clearance of acute EBV infection and ongoing immune surveillance that limits EBV-driven malignancies[6][5][4]. Therapeutic manipulation of EBV peptide–MHC complexes includes T cell therapies and experimental TCR-mimic antibodies for adoptive immunotherapy[4]. Notes: - This entry is not a single gene or protein, but refers to the MHC-presented viral peptide complex—often the key determinant in adaptive immunotherapy or immune monitoring for EBV-associated diseases. - No conventional small-molecule inhibitors target this complex; drug interaction is via immunotherapeutic modalities (cell therapies, antibody engineering).

Other names

EBV pMHC complexEpstein–Barr virus pMHC complexEBV peptide–HLA complex

Induction or enhancement of T-cell mediated immunity by presentation of viral peptides Targeted cell killing through cytotoxic T cells recognizing EBV-derived peptides on MHC molecules